Stem Cell Therapy for the Coronavirus COVID-19 Pandemic

Stem Cell Therapy for the Coronavirus COVID-19 Pandemic

March 17, 2020 – Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma reports on its therapy for the Coronavirus (COVID-19) pandemic.  Recent umbilical cord stem cell therapies in China to fight the Coronavirus are producing encouraging emergency results. Vitro Biopharma has the highest level of umbilical cord stem cell technology to reduce death rates Read More »


Stem Cell Therapy for the Coronavirus COVID-19 Pandemic

covid 19

March 17, 2020 – Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma reports on its therapy for the Coronavirus (COVID-19) pandemic. 

Recent umbilical cord stem cell therapies in China to fight the Coronavirus are producing encouraging emergency results. Vitro Biopharma has the highest level of umbilical cord stem cell technology to reduce death rates due to the Coronavirus pandemic. patient-saved-stem-cell therapy-to-treat-severe-covid-19-could-save-lives-now

Dr. Jim Musick, Ph.D., CEO said, “As the world struggles to deal with the COVID-19 pandemic, it is important to consider stem cell therapy to reduce death rates. This is supported by clinical studies and clinical trials are underway to substantiate safety and efficacy. Vitro Biopharma is ideally suited to provide high quality stem cells to US patients, produced under strict quality control in a cGMP, ISO9001 & ISO13485 Certified environment. Our umbilical cord AlloRx™ Stem Cells and stem cell growth media MSC-Gro™ have been used in the treatment of hundreds of patients without adverse events and show efficacy in treatment of COPD, osteoarthritis, multiple sclerosis and Alzheimer’s disease.

Out of years of research, we developed our patent-pending and proprietary line of umbilical cord derived stem cells AlloRx™ Stem Cells now being used in offshore regenerative medicine clinical trials. Our stem cells are used in regenerative medicine clinical trials with our partner in the Cayman Islands

Vitro Biopharma has a patent-pending, proprietary and scalable manufacturing platform to provide stem cell therapies to critically ill Coronavirus patients. Our stem cells have been shown to be safe in Phase I protocols as we also gain evidence of efficacy.

We are in contact with federal, state and local governments to inform them of our AlloRx ™ Stem Cell therapy option for Coronavirus infections.. The pandemic deserves consideration of all therapeutic options and there is evidence that stem cell therapy reduces the death rate from Coronavirus COVID-19 infections. We believe that critically ill patients should have the right to try stem cell therapy in the United States.”

Dr. James Musick Chief Executive Officer
Vitro Biopharma (303) 550-2778
Source: Vitro Diagnostics, Inc

Forward-Looking Statements
Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company’s auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements”. Such forward looking statements are identified by words such as “intends,”
“anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures.

Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements.

Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

Lethean (IntenseCoin) Explained: The Decentralized VPN Cryptocurrency Project

lethean logo

by Jacob Woods

What is Lethean

Lethean, incorporated in the UK, has created a decentralized VPN marketplace. Lethean has been described as the “first Mainnet P2P Virtual Private Network backed by the Blockchain.”

Users can take advantage of the browser extension or the full client VPN. Anyone can mine the coin or operate an exit node to earn LTHN. LTHN is used as payment for the VPN services. This VPN marketplace allows you to select a specific country, price, and speed.

LTHN is a proof-of-work coin based on CryptoNote. Monero is another example of a CryptoNote coin. Lethean, like XMR, uses ring signatures and one-time keys to make transactions unlinkable and untraceable. LTHN uses the CryptoNightR hashing algorithm. LTHN implemented CryptoNightR 10 hours before Monero did.

Introducing Facebook Cryptocurrency Libra

libra cryptocurrency logo

Welcome to Libra. Libra is a global, digitally native, reserve-backed cryptocurrency built on the foundation of blockchain technology. People will be able to send, receive, spend, and secure their money, enabling a more inclusive global financial system.

Our mission is to enable a simple global currency and financial infrastructure that empowers billions of people, and our hope is to create more access to better, cheaper, and open financial services — no matter who you are, where you live, what you do, or how much you have. Find out more at Read the Libra White Paper.

More about Libra from The Verge

Also see “Libra: Cryptocurrency By Facebook (In 5 Minutes)” from

MRI Interventions Reports 52% Increase in First Quarter Revenue

MRI Interventions logo

Record $2.5 million quarterly revenue driven by growth across entire portfolio OTCQB: MRIC) (the “Company”) today announced financial results for its first fiscal quarter ended March 31, 2019.

First Quarter 2019 Highlights

  • Increased first quarter revenue 52% year-over-year to $2.5 million.
  • Reported $1.6 million in quarterly functional neurosurgery revenue, an increase of 38% over the prior year first quarter.
  • Reported biologics and drug delivery revenue of $382,000, an increase of 93% over the prior year, including first European shipments to Lysogene for use in their P4-SAF-302 trial.
  • Reported capital sales and other services revenue of $486,000, which includes two system sales; the systems sales, combined with three evaluation installations, bring total U.S. installed base to 63 systems.
  • Completed 175 procedures across the Company’s product portfolio.
  • Completed the transfer of the V-Tag 510(k) from Voyager Therapeutics, Inc. and completed initial clinical builds.
  • Generated gross margin of 64%.
  • Maintained reduction of cash used in operations to $609,000, which included annual bonus compensation and semi-annual interest payment.

Is the Bitcoin Beast Awakening?

bitcoin illustration

After languishing in a bear market that began when BTC hit $20,000 on December 17, 2017, Bitcoin has recently shown some life. On April 2nd the price rose 20% on high volume. The scuttlebut is a whale bought most of it, but either way the entire crypto market rose with its leader.

In the last 7 days Bloom BLT us up 84%, Bitcoin Cash BCH is up 69% and Litecoin LTC is up 42%. Total market cap for all coins went from 143B on March 31st to a high of 183B on April 3rd. It appears the beast could be awakening.

What would you buy now besides the leaders like BTC and Ethereum?

I got my eye on a few. I’ll keep you posted.